DSP-0390 plus Atezolizumab for Small Cell Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called DSP-0390 combined with atezolizumab (an immunotherapy) in patients with small cell lung cancer who have already completed initial chemotherapy treatment. The goal is to see if this combination can help prevent the cancer from coming back or growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with small cell lung cancer confirmed by biopsy or cell sample
- You completed 3–4 cycles of initial chemotherapy and immunotherapy without your cancer getting worse
- Your cancer is measurable on imaging scans (RECIST 1.1 criteria)
- You are at least 18 years old and able to care for yourself with minimal help (ECOG score 0–2)
- Your blood counts and organ function (liver, kidneys) are adequate; specific lab values will be checked
- You agree to use birth control during treatment and for 6 months after, if you can have children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This Phase 1/2 trial tests whether a gene therapy called Reqorsa given with atezolizumab can help people with extensive-stage small cell lung cancer (ES-SCLC) stay controlled after their first chemo. It may help by boosting the immune system to keep the cancer from growing again.
This trial tests a new combination of two drugs (sintilimab and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after prior immunotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.